Part D Rebates and the Numbers Game: Pharma Readies for Post-Election Deficit Fight
This article was originally published in RPM Report
PhRMA CEO Castellani readies for 2013 deficit reduction legislative debate by laying out how much money in the system is at stake.
You may also be interested in...
Part D Rebates: Talking Points Continue, But Deficit Deal Elusive
Once again the President is calling for rebates on prescription drugs sold under Medicare Part D. But without a big deficit deal involving entitlement reform, is there any way to enact them?
Merck CEO Frazier Stands Alone As Pharma Signatory Urging Fiscal Cliff Budget Deal
Coalition of business leaders that includes Merck CEO Ken Frazier pushes for deficit deal to avert sequestration. The reason seems simple: corporate tax reform.
The End Of Pay-For-Delay? FTC Sees An Opportunity In AndroGel Lawsuit
Reverse payment settlements are a popular tactic for settling patent disputes between brand companies and their generic competitors. The Federal Trade Commission has aggressively (but mostly unsuccessfully) fought “pay-for-delay” deals in the courts, arguing that they drive up drug prices. Now FTC has its best chance yet at convincing the Supreme Court to hear the issue. Is this the end of pay-for-delay?